Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED TO HOST INVESTOR DAYS IN AUSTRALIA
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce upcoming investor days at several major Australian cities in February.
Prima CEO, Matthew Lehman will host the sessions, to be held in Sydney, Melbourne, Brisbane and Perth, in the week commencing 4 February
Mr. Lehman will provide an update on the Company s business and attendees will have an opportunity for Q&A.
Details of dates and venues are provided below.
Shareholders and other interested parties are kindly requested to help assure appropriate accommodations by sending an RSVP by email to enquiries@primabiomed.com.au and identify the city of
attendance by Friday 1st February.
BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop
innovative treatment options for patients and maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
For further information please contact:
Brown, Prima BioMed Ltd.
+1 (919) 710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de
BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284